Susan C Short

List of Publications by Year in descending order

103 papers	6,038 citations	101543 36 h-index	79698 73 g-index
110 all docs	110 docs citations	110 times ranked	7564 citing authors

#	Article	IF	Citations
1	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186.	27.6	826
2	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
3	Low-dose hypersensitivity: current status and possible mechanisms. International Journal of Radiation Oncology Biology Physics, 2001, 49, 379-389.	0.8	508
4	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	27.8	320
5	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine, 2018, 10, .	12.4	288
6	ESTRO-ACROP guideline â€œtarget delineation of glioblastomasâ€• Radiotherapy and Oncology, 2016, 118, 35-42.	0.6	286
7	Systematic Review of Synthetic Computed Tomography Generation Methodologies for Use in Magnetic Resonance Imagingâ€“Only Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 199-217.	0.8	235
8	ATR-dependent radiation-induced Î³H2AX foci in bystander primary human astrocytes and glioma cells. Oncogene, 2007, 26, 993-1002.	5.9	179
9	Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell, 2022, 185, 2184-2199.e16.	28.9	163
10	Senolytics and senostatics as adjuvant tumour therapy. EBioMedicine, 2019, 41, 683-692.	6.1	136
11	Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. International Journal of Radiation Biology, 2001, 77, 655-664.	1.8	110
12	RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells. Stem Cell Reports, 2017, 8, 125-139.	4.8	100
13	Effects of cell cycle phase on low-dose hyper-radiosensitivity. International Journal of Radiation Biology, 2003, 79, 99-105.	1.8	90
14	Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. Neuro-Oncology, 2011, 13, 487-499.	1.2	79
15	Thalidomide as an anti-angiogenic agent in relapsed gliomas. Journal of Neuro-Oncology, 2001, 51, 41-45.	2.9	75
16	Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom. Clinical Cancer Research, 2006, 12, 7025-7032.	7.0	75
17	The response of human glioma cell lines to low-dose radiation exposure. International Journal of Radiation Biology, 1999, 75, 1341-1348.	1.8	73
18	A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. British Journal of Cancer, 2021, 124, 1379-1387.	6.4	66

#	Article	IF	Citations
19	NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget, 0, 7, 41251-41264.	1.8	65
20	Low-Dose Reduction in Transformation Frequency Compared to Unirradiated Controls: The Role of Hyper-radiosensitivity to Cell Death. Radiation Research, 2003, 159, 433-436.	1.5	64
21	Low dose hyper-radiosensitivity in metastatic tumors. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1190-1195.	0.8	63
22	DNA Damage Responses at Low Radiation Doses. Radiation Research, 2005, 164, 292-302.	1.5	62
23	Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) â€“ protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer, 2016, 16, 769.	2.6	62
24	A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clinical Oncology, 2004, 16, 569-574.	1.4	61
25	Pituitary dysfunction following cranial radiotherapy for adultâ€onset nonpituitary brain tumours. Clinical Endocrinology, 2016, 84, 372-379.	2.4	61
26	Cytotoxic Effects of Temozolomide and Radiation are Additive- and Schedule-Dependent. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1511-1519.	0.8	57
27	Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro-Oncology, 2016, 18, 518-527.	1.2	57
28	Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation. Pituitary, 2014, 17, 530-538.	2.9	56
29	Prediction of clinical outcome in glioblastoma using a biologically relevant nineâ€microRNA signature. Molecular Oncology, 2015, 9, 704-714.	4.6	56
30	KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice. Science Translational Medicine, 2018, 10, .	12.4	54
31	PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 2018, 8, 12-16.	1.7	51
32	Development of clinical simultaneous SPECT/MRI. British Journal of Radiology, 2018, 91, 20160690.	2.2	51
33	Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. Clinical and Experimental Immunology, 2020, 200, 33-44.	2.6	51
34	DNA repair after irradiation in glioma cells and normal human astrocytes. Neuro-Oncology, 2007, 9, 404-411.	1.2	49
35	EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma. Oncogene, 2020, 39, 3041-3055.	5.9	42
36	Diffuse pigmented villonodular synovitis of the foot and ankle treated with surgery and radiotherapy. International Orthopaedics, 2005, 29, 403-405.	1.9	39

#	Article	IF	Citations
37	The evaluation of low dose hyper-radiosensitivity in normal human skin. Radiotherapy and Oncology, 2004, 70, 319-329.	0.6	38
38	Acute Chemotherapyâ€“Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom. Clinical Cancer Research, 2006, 12, 7033-7038.	7.0	36
39	Low-dose hyperradiosensitivity of human glioblastoma cell linesin vitrodoes not translate into improved outcome of ultrafractionated radiotherapyin vivo. International Journal of Radiation Biology, 2005, 81, 751-758.	1.8	35
40	The Role of Autophagy in Clinical Practice. Clinical Oncology, 2012, 24, 387-395.	1.4	35
41	Glycolysis and Fatty Acid Oxidation Inhibition Improves Survival in Glioblastoma. Frontiers in Oncology, 2021, 11, 633210.	2.8	30
42	Ultrafractionation in A7 human malignant glioma in nude mice. International Journal of Radiation Biology, 2003, 79, 377-383.	1.8	29
43	Effects of cell cycle phase on low-dose hyper-radiosensitivity. International Journal of Radiation Biology, 2003, 79, 99-105.	1.8	29
44	Management of Glioblastoma Multiforme in HIV Patients: a Case Series and Review of Published Studies. Clinical Oncology, 2009, 21, 591-597.	1.4	28
45	High-content analysis of tumour cell invasion in three-dimensional spheroid assays. Oncoscience, 2015, 2, 596-606.	2.2	27
46	Temozolomide as second-line chemotherapy for relapsed gliomas. Journal of Neuro-Oncology, 2002, 57, 247-251.	2.9	26
47	Multi-disciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study. Radiation Oncology, 2013, 8, 156.	2.7	26
48	Towards the production of radiotherapy treatment shells on 3D printers using data derived from DICOM CT and MRI: preclinical feasibility studies. Journal of Radiotherapy in Practice, 2015, 14, 92-98.	0.5	26
49	Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro-Oncology, 2022, 24, 528-540.	1.2	26
50	Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscleâ€invasive bladder cancer. International Journal of Cancer, 2015, 136, 709-720.	5.1	24
51	Meningioma Causing Visual Impairment: Outcomes and Toxicity After Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, e179-e186.	0.8	22
52	Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Molecular Therapy - Oncolytics, 2017, 5, 75-86.	4.4	22
53	Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells. Neuro-Oncology, 2018, 20, 203-214.	1.2	22
54	Evaluating the repeatability and set-up sensitivity of a large field of view distortion phantom and software for magnetic resonance-only radiotherapy. Physics and Imaging in Radiation Oncology, 2018, 6, 31-38.	2.9	22

#	Article	IF	Citations
55	Position statement on ethics, equipoise and research on charged particle radiation therapy. Journal of Medical Ethics, 2014, 40, 572-575.	1.8	20
56	A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. Molecular Oncology, 2016, 10, 1296-1304.	4.6	19
57	Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA Mismatch Repair Deficient Cells. Clinical Cancer Research, 2017, 23, 2880-2890.	7.0	19
58	Hypothalamicâ€pituitary axis irradiation dose thresholds for the development of hypopituitarism in adultâ€onset gliomas. Clinical Endocrinology, 2019, 91, 131-140.	2.4	19
59	Effects of cell cycle phase on low-dose hyper-radiosensitivity. International Journal of Radiation Biology, 2003, 79, 99-105.	1.8	19
60	Cellular response to low-dose irradiation. Clinical Oncology, 1998, 10, 73-77.	1.4	18
61	Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms. Journal of Neuro-Oncology, 2020, 147, 485-494.	2.9	16
62	Diagnostic delay and survival in high-grade gliomas â€“ evidence of the â€˜waiting time paradoxâ€™?. British Journal of Neurosurgery, 2015, 29, 520-523.	0.8	15
63	Dose- and Time-Dependent Changes in Gene Expression in Human Glioma Cells after Low Radiation Doses. Radiation Research, 2007, 168, 199-208.	1.5	13
64	Sequential Transformation of Mesenchymal Stem Cells is Associated with Increased Radiosensitivity and Reduced DNA Repair Capacity. Radiation Research, 2013, 179, 698-706.	1.5	13
65	shRNAâ€mediated PPARÎ± knockdown in human glioma stem cells reduces in vitro proliferation and inhibits orthotopic xenograft tumour growth. Journal of Pathology, 2019, 247, 422-434.	4.5	13
66	Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma. Journal of Neuro-Oncology, 2014, 117, 243-251.	2.9	12
67	FGFR1 Expression and Role in Migration in Low and High Grade Pediatric Gliomas. Frontiers in Oncology, 2019, 9, 103.	2.8	12
68	Prognostic microRNAs in high-grade glioma reveal a link to oligodendrocyte precursor differentiation. Oncoscience, 2014, 2, 252-262.	2.2	12
69	Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy. Radiation Oncology, 2014, 9, 103.	2.7	11
70	Drug Resistance in Glioma Cells Induced by a Mesenchymalâ€“Amoeboid Migratory Switch. Biomedicines, 2022, 10, 9.	3.2	10
71	Intensity standardization of MRI prior to radiomic feature extraction for artificial intelligence research in gliomaâ€”a systematic review. European Radiology, 2022, 32, 7014-7025.	4.5	10
72	Benchmarking of a treatment planning system for spot scanning proton therapy: Comparison and analysis of robustness to setup errors of photon IMRT and proton SFUD treatment plans of base of skull meningioma. Medical Physics, 2014, 41, 111710.	3.0	9

#	Article	IF	Citations
73	Biological dosimetry for breast cancer radiotherapy: a comparison of external beam and intraoperative radiotherapy. SpringerPlus, 2014, 3, 329.	1.2	8
74	How to analyse the spatiotemporal tumour samples needed to investigate cancer evolution: A case study using paired primary and recurrent glioblastoma. International Journal of Cancer, 2018, 142, 1620-1626.	5.1	8
75	Primary Central Nervous System Lymphoma with Testicular Relapse. Clinical Oncology, 2004, 16, 193-195.	1.4	7
76	BRCA1andBRCA2heterozygosity in embryonic stem cells reduces radiation-induced Rad51 focus formation but is not associated with radiosensitivity. International Journal of Radiation Biology, 2010, 86, 1095-1105.	1.8	7
77	Changes in mast cell number and stem cell factor expression in human skin after radiotherapy for breast cancer. Radiotherapy and Oncology, 2014, 111, 206-211.	0.6	7
78	Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial. Neuro-Oncology Advances, 2020, 2, vdaa046.	0.7	7
79	Hematopoietic stem cell gene therapy targeting TGFÎ² enhances the efficacy of irradiation therapy in a preclinical glioblastoma model. , 2021, 9, e001143.		7
80	HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiforme. BMC Cancer, 2022, 22, 400.	2.6	7
81	Chemically-induced neurite-like outgrowth reveals multicellular network function in patient-derived glioblastoma cells. Journal of Cell Science, 2019, 132, .	2.0	6
82	Radiosurgery for brain tumours. BMJ: British Medical Journal, 2010, 340, c3247-c3247.	2.3	5
83	Patient Involvement in the Design of a Randomised Trial of Proton Beam Radiotherapy Versus Standard Radiotherapy for Good Prognosis Glioma. Clinical Oncology, 2020, 32, 89-92.	1.4	5
84	Profiling cytotoxic microRNAs in pediatric and adult glioblastoma cells by high-content screening, identification, and validation of miR-1300. Oncogene, 2020, 39, 5292-5306.	5.9	5
85	Long-term impact of adult WHO grade II or III gliomas on health-related quality of life: A systematic review. Neuro-Oncology Practice, 2022, 9, 3-17.	1.6	5
86	GSK-3 Inhibition Is Cytotoxic in Glioma Stem Cells through Centrosome Destabilization and Enhances the Effect of Radiotherapy in Orthotopic Models. Cancers, 2021, 13, 5939.	3.7	5
87	Science in Focus: MicroRNA in Glioma â€“ Potential as Biomarkers and Therapeutic Targets. Clinical Oncology, 2016, 28, 543-546.	1.4	4
88	A novel workflow for three-dimensional analysis of tumour cell migration. Interface Focus, 2020, 10, 20190070.	3.0	4
89	Survival from brain tumours in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S102-S103.	6.4	3
90	Radiobiology and vascular targeting in glioma. Current Opinion in Neurology, 2003, 16, 651-655.	3.6	2

#	Article	IF	Citations
91	Increased replication stress and R-loop accumulation in EGFRvIII-expressing glioblastoma present new therapeutic opportunities. Neuro-Oncology Advances, 2022, 4, vdab180.	0.7	2
92	Neuro-Oncology. , 0, , 771-822.		1
93	Re-irradiation of brain tumours â€" evidence, indications and limitations. European Journal of Cancer, 2009, 45, 410-411.	2.8	1
94	Chromatin remodelling to facilitate treatment resistance in glioblastoma. Neuro-Oncology, 2019, 21, iv7-iv7.	1.2	1
95	Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. Neuro-Oncology Practice, 2020, 7, 249-259.	1.6	1
96	Establishing a Link Between Commonly Reported Toxicities and Tumour Location in Brain Tumour Patients Treated With Volumetric-modulated Arc Radiotherapy. Clinical Oncology, 2021, 33, e97-e98.	1.4	1
97	CTIM-14. PELAREOREP AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) WITH STANDARD CHEMORADIOTHERAPY/ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA MULTIFORME (GBM) PATIENTS: REOGLIO PHASE I TRIAL RESULTS. Neuro-Oncology, 2020, 22, ii35-ii36.	1.2	1
98	Brain Tumours. Medical Radiology, 2016, , 127-142.	0.1	0
99	Patient engagement in the design of a randomised trial of proton beam radiotherapy versus photon radiotherapy for good prognosis glioma. Neuro-Oncology, 2019, 21, iv10-iv11.	1.2	0
100	The impact of the neuro-oncology research radiographer role in the effective facilitation of an advanced imaging study in glioblastoma. Neuro-Oncology, 2019, 21, iv17-iv17.	1.2	0
101	Highlights of the inaugural ten â€" the launch of Neuro-Oncology Advances. Neuro-Oncology Advances, 2019, 1, vdz016.	0.7	0
102	Using Retinoids to Increase Radioiodine Uptake in Thyroid Cancer. , 2009, , 991-999.		0
103	Sub-acute blindness in a patient with a temporal lobe astrocytoma. BMJ Case Reports, 2009, 2009, bcr0120091513-bcr0120091513.	0.5	0